10,500 Shares in Zoetis Inc. $ZTS Bought by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 10,500 shares of the company’s stock, valued at approximately $755,000.

Other large investors also recently modified their holdings of the company. J. Stern & Co. LLP grew its holdings in shares of Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after acquiring an additional 23,877,416 shares in the last quarter. Norges Bank bought a new stake in Zoetis during the fourth quarter worth about $734,425,000. Vanguard Group Inc. grew its stake in Zoetis by 12.9% in the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares in the last quarter. Ruane Cunniff & Goldfarb L.P. acquired a new position in shares of Zoetis during the 1st quarter worth approximately $286,660,000. Finally, Van ECK Associates Corp increased its position in shares of Zoetis by 269.0% during the 4th quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock worth $300,340,000 after purchasing an additional 1,740,113 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Down 2.9%

Shares of ZTS stock opened at $73.64 on Friday. Zoetis Inc. has a 12-month low of $71.45 and a 12-month high of $160.48. The company has a market capitalization of $30.43 billion, a PE ratio of 12.13, a price-to-earnings-growth ratio of 1.31 and a beta of 0.74. The firm has a 50 day moving average price of $76.30 and a two-hundred day moving average price of $99.01. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, analysts predict that Zoetis Inc. will post 6.19 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is currently 34.93%.

Analysts Set New Price Targets

ZTS has been the subject of several recent analyst reports. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. TD Cowen lowered their target price on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. Argus restated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Morgan Stanley set a $85.00 price target on shares of Zoetis in a research report on Friday, August 7th. Finally, UBS Group cut their price target on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $109.62.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.